Expanded Access to Cefiderocol for the Intravenous Treatment of Severe Gram Negative Bacterial Infections

NCT03780140 | Unknown

• 1 other identifier: S-649266-EA
• Study Type: expanded_access
• Target: N/A
• Locations: 0 countries
• Sites: N/A

Brief Summary

Expanded access may be provided for cefiderocol for qualified patients who have limited treatment options and are not eligible for a clinical trial.

Conditions

Bacterial Infections

Keywords

S-649266; cefiderocol; Gram-negative

Interventions

Cefiderocol DRUG

Cefiderocol for intravenous infusion

Also known as: S-649266

Eligibility Criteria

• Sex: all
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

Hospitalized patients with serious Gram-negative bacterial infections and who have limited treatment options and are not eligible for a clinical trial.

Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.

Sponsors & Collaborators

• Shionogi: lead

Related Links

• Shionogi Compassionate Use

MeSH Terms

Conditions

Bacterial Infections

Interventions

Cefiderocol

Condition Hierarchy (Ancestors)

Bacterial Infections and Mycoses; Infections

Intervention Hierarchy (Ancestors)

Cephalosporins; beta-Lactams; Lactams; Amides; Organic Chemicals; Thiazines; Sulfur Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Heterocyclic Compounds

Study Officials

• Shionogi Clinical Trials Administrator Clinical Support Help Line

  Shionogi

  STUDY DIRECTOR

Study Design

• Study Type: expanded access
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 17, 2018
• First Posted: December 19, 2018
• Last Updated: February 28, 2020

Record last verified: 2020-02